Newsletter
Every new paper in this field, in your inbox.
A systematic review and meta-analysis encompassing 14 studies reveal that colorectal cancer patients with peritoneal metastases experience enhanced overall survival (OS) and relapse-free survival (RFS) following cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Compared to control regimens, the CRS + HIPEC approach markedly…
A narrative review assessed complications linked to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients battling peritoneal metastasis. It cataloged categories of complications, including surgical, chemotherapy-related, and systemic issues, emphasizing the high morbidity associated with these interventions. The findings advocate for stringent patient selection, precise…
A multisocietal consensus has endorsed cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treating diffuse malignant peritoneal mesothelioma (DMPM). An expert panel, acknowledging the limited efficacy of systemic chemotherapy, strongly recommended this approach for a select subgroup of patients. Despite low evidence certainty, the…
A bicentric analysis revealed that patients with colorectal cancer peritoneal metastases (crpm), particularly when isolated or with limited extraperitoneal metastases (epm), experience significantly improved median overall survival (58 months vs. 39 months) following cytoreductive surgery. The study involved 413 patients, demonstrating similar postoperative outcomes between…
A systematic review and meta-analysis of 746 patients revealed that cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) significantly enhances median overall survival to 32.3 months, compared to 14.5 months with systemic chemotherapy alone. In patients undergoing complete cytoreduction, the study reported a major morbidity rate of…
Analysis of 2,773 colorectal peritoneal metastasis patients revealed that those diagnosed through screening had significantly better survival rates and more often received curative treatment. Specifically, 7% were screen-detected, with a median overall survival of 20 months compared to 10.8 months for clinically detected patients. Additionally,…
A multidisciplinary Enhanced Recovery After Surgery (ERAS) program significantly improved compliance and reduced hospital stays for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Compliance with ERAS protocols rose from 32.8% to 70.8%. Concurrently, the median length of stay decreased from 14 to 9…
A meta-analysis of 12 randomized controlled trials involving 1,181 gastric cancer patients demonstrated that hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improved survival rates compared to control groups at 1, 2, 3, and 5 years. The recurrence rates were notably lower in the HIPEC group, and higher…
A prospective clinical study evaluates the predictive effects of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in peritoneal lavage fluid for metachronous peritoneal metastasis (PM) in gastric cancer patients following radical resection. A total of 200 patients will be monitored over two years,…
Results indicate that diffusion-weighted MRI (dw-MRI) demonstrates significant accuracy in evaluating the peritoneal cancer index (PCI) in colorectal cancer patients with peritoneal metastases. In a cohort of 87 patients, a strong correlation was found between MRI-derived PCI and histopathology (0.77), with surgical PCI showing excellent…
